August 10, 2020

First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine

Category: Article Summary

Topic: Vaccines and Immunity

• [pre-print, not peer-reviewed] NVX-CoV2373, a recombinant nanoparticle vaccine, induced mean anti-spike IgG and neutralizing antibody responses that exceeded the mean responses in sera from convalescent COVID-19 patients with clinically significant illness. There were no serious adverse events and reactogenicity was mainly mild and not long-lasting. 

 Keech et al. (Aug 6, 2020). First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine. Pre-print downloaded Aug 10 from https://doi.org/10.1101/2020.08.05.20168435